Cited by 131Treatment of Major DepressionSchizophrenia research and treatmentTryptophan and brain disorders

The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.

Minocycline: Therapeutic Potential in Psychiatry

Dean, Olivia M., Data-Franco, João, Giorlando, Francesco, Berk, Michael·2012·CNS Drugs

DOI 10.2165/11632000-000000000-00000

Open this paper in CoChat — free account

Abstract

Pharmacological interventions to treat psychiatric illness have previously focused on modifying dysfunctional neurotransmitter systems to improve symptoms. However, imperfect understanding of the aetiology of these heterogeneous syndromes has been associated with poor treatment outcomes for many individuals. Growing evidence suggests that oxidative stress, inflammation, changes in glutamatergic pathways and neurotrophins play important roles in many psychiatric illnesses including mood disorders, schizophrenia and addiction. These novel insights into pathophysiology allow new treatment targets to be explored. Minocycline is an antibiotic that can modulate glutamate-induced excitotoxicity, and has antioxidant, anti-inflammatory and neuroprotective effects. Given that these mechanisms overlap with the newly understood pathophysiological pathways, minocycline has potential as an adjunctive treatment in psychiatry. To date there have been promising clinical indications that minocycline may be a useful treatment in psychiatry, albeit from small trials most of which were not placebo controlled. Case reports of individuals with schizophrenia, psychotic symptoms and bipolar depression have shown serendipitous benefits of minocycline treatment on psychiatric symptoms. Minocycline has been trialled in open-label or small randomized controlled trials in psychiatry. Results vary, with findings supporting use in schizophrenia, but showing less benefit for nicotine dependence and obsessive-compulsive disorder. Given the limited data from rigorous clinical trials, further research is required. However, taken together, the current evidence suggests minocycline may be a promising novel therapy in psychiatry.

Integrity signals

Registry

Crossref · 10.2165/11632000-000000000-00000

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2
Kernt, M. (2010) · Clinical ophthalmology · doi:10.2147/opth.s11216 · Cited by 34
Retracted
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Oxidative stress and neurodegeneration: where are we now?
Halliwell, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03907.x · Cited by 2,614
Inflammation is detrimental for neurogenesis in adult brain
Ekdahl, C. T., Claasen, J.-H., Bonde, S., Kokaia, Z., & Lindvall, O. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2234031100 · Cited by 1,559
Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Self-citation
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069
Self-citation
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice
Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V. O., Li, M., Sarang, S. S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,069
Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease
Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,060
Interleukin (IL)-6, Tumour Necrosis Factor Alpha (TNF-α) and Soluble Interleukin-2 Receptors (SIL-2R) Are Elevated in Patients with Major Depressive Disorder: A Meta-Analysis and Meta-Regression
Liu, Y., Ho, R. C.-M., & Mak, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.003 · Cited by 948
The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression
Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894

Show all 98 references

Research works printed but not linked: 2

Garner, 2003, Cochrane Database Syst Rev, &NA;, CD002086
Levine, 1996, Am J Psychiatry, 153, 582

Sorted by citations

Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment
Millan, M. J., Fone, K. C. F., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 376
Post-Operative Cognitive Dysfunction: An exploration of the inflammatory hypothesis and novel therapies
Skvarc, D., Berk, M., Byrne, L. K., Dean, O. M., Dodd, S., Lewis, M., Marriott, A., Moore, E. M., Morris, G., Page, R. S., et al. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.11.011 · Cited by 318
Self-citation
Biomarkers and clinical staging in psychiatry
McGorry, P. D., Keshavan, M. S., Goldstone, S. D., Amminger, G. P., Allott, K., Berk, M., Lavoie, S., Pantelis, C., Yung, A. R., Wood, S. J., et al. (2014) · World Psychiatry · doi:10.1002/wps.20144 · Cited by 324
Self-citation
Cognitive remission: a novel objective for the treatment of major depression?
Bortolato, B., Miskowiak, K. W., Köhler, C. A., Maes, M., Fernandes, B. S., Berk, M., & Carvalho, A. F. (2016) · BMC Medicine · doi:10.1186/s12916-016-0560-3 · Cited by 252
Self-citation
Microglial activation and progressive brain changes in schizophrenia
Laskaris, L., Biase, M. A. D., Everall, I., Chana, G., Christopoulos, A., Skafidas, E. S., Cropley, V., & Pantelis, C. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13364 · Cited by 237
Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia
Mattei, D., Djodari-Irani, A., Hadar, R., Pelz, A., de Cossío, L. F., Goetz, T., Matyash, M., Kettenmann, H., Winter, C., & Wolf, S. A. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.01.019 · Cited by 195
Is bipolar disorder an inflammatory condition? The relevance of microglial activation
Stertz, L., Magalhães, P. V. D. S., & Kapczinski, F. P. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835aa4b4 · Cited by 184
Effectiveness and tolerance of anti‐inflammatory drugs' add‐on therapy in major mental disorders: a systematic qualitative review
Fond, G. B., Hamdani, N., Kapczinski, F. P., Boukouaci, W., Drancourt, N., Dargél, A., Oliveira, J., Guen, E. L., Marlinge, E., Tamouza, R., et al. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12211 · Cited by 175
The Efficacy of Adjunctive N-Acetylcysteine in Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Trial
Berk, M., Dean, O. M., Cotton, S. M., Jeavons, S., Tanious, M., Kohlmann, K., Hewitt, K., Moss, K., Allwang, C., Schapkaitz, I., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08454 · Cited by 172
Self-citation
Microglial dysfunction connects depression and Alzheimer’s disease
Santos, L. E., Beckman, D., & Ferreira, S. T. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.11.011 · Cited by 154
Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries
Davis, J., Moylan, S., Harvey, B. H., Maes, M. H. J., & Berk, M. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414533012 · Cited by 145
Self-citation
Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways
Monte, A. S., de Souza, G. C., McIntyre, R. S., Soczynska, J. K., Santos, J. V. D., Cordeiro, R. C., Ribeiro, B. M. M., de Lucena, D. F., Vasconcelos, S. M. M., de Sousa, F. C. F., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113503506 · Cited by 124
Neuroimmune Basis of Methamphetamine Toxicity
Loftis, J. M., & Janowsky, A. J. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801284-0.00007-5 · Cited by 123
Molecular Mechanisms of Bipolar Disorder: Progress Made and Future Challenges
Kim, Y., Santos, R., Gage, F. H., & Marchetto, M. C. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00030 · Cited by 127
Prenatal valproate in rodents as a tool to understand the neural underpinnings of social dysfunctions in autism spectrum disorder
Tartaglione, A. M., Schiavi, S., Calamandrei, G., & Trezza, V. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.024 · Cited by 117
Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: Comparison with schizophrenia
Altamura, A. C., Buoli, M., & Pozzoli, S. M. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12089 · Cited by 113
Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial
Dean, O. M., Kanchanatawan, B., Ashton, M. M., Mohebbi, M., Ng, C. H., Maes, M. H. J., Berk, L., Sughondhabirom, A., Tangwongchai, S., Singh, A., et al. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867417709357 · Cited by 106
Self-citation
Putative neuroprotective agents in neuropsychiatric disorders
Dodd, S., Maes, M. H. J., Anderson, G., Dean, O. M., Moylan, S., & Berk, M. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.007 · Cited by 105
Self-citation
Staging bipolar disorder: clinical, biochemical, and functional correlates
Grande, I., Magalhães, P. V. D. S., Chendo, I., Stertz, L., Panizzutti, B., Colpo, G. D., Rosa, A. R., Gama, C. S., Kapczinski, F. P., & Vieta, E. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12268 · Cited by 102
Indoleamine-2,3-Dioxygenase/Kynurenine Pathway as a Potential Pharmacological Target to Treat Depression Associated with Diabetes
Dias, I. C. D. S., Carabelli, B., Ishii, D. K., Morais, H., de Carvalho, M. C., de Souza, L. E. R., Zanata, S. M., Brandão, M. L., Cunha, T. M., Ferraz, A. C., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9617-0 · Cited by 88
Major depressive disorder as a neuro-immune disorder: Origin, mechanisms, and therapeutic opportunities
Réus, G. Z., Manosso, L. M., Quevedo, J., & Carvalho, A. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105425 · Cited by 94
Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways
Anderson, G., Maes, M. H. J., & Berk, M. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.07.016 · Cited by 86
Self-citation
Tumor Necrosis Factor-α Modulates Cerebral Aneurysm Formation and Rupture
Starke, R. M., Raper, D. M. S., Ding, D., Chalouhi, N., Owens, G. K., Hasan, D. M., Medel, R., & Dumont, A. S. (2013) · Translational Stroke Research · doi:10.1007/s12975-013-0287-9 · Cited by 84
Are the emergence of affective disturbances in neuropathic pain states contingent on supraspinal neuroinflammation?
Fiore, N. T., & Austin, P. J. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.04.012 · Cited by 80
The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review
Girgis, R. R., Zoghbi, A. W., Javitt, D. C., & Lieberman, J. A. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.006 · Cited by 75
Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis
Panizzutti, B., Skvarc, D., Lin, S. C., Croce, S., Meehan, A., Bortolasci, C. C., Marx, W., Walker, A. J., Hasebe, K., Kavanagh, B. E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065250 · Cited by 72
Self-citation
Microglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric Disorders
Lisboa, S. F. D. S., Gomes, F. V., Guimarães, F. S., & Campos, A. C. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00005 · Cited by 69
Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder
Pfaffenseller, B., Fries, G. R., Wollenhaupt-Aguiar, B., Colpo, G. D., Stertz, L., Panizzutti, B., Magalhães, P. V., & Kapczinski, F. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811981 · Cited by 68
Resolving and Rescuing Developmental Miswiring in a Mouse Model of Cognitive Impairment
Chini, M., Pöpplau, J. A., Lindemann, C., Carol-Perdiguer, L., Hnida, M., Oberlander, V. C., Xu, X., Ahlbeck, J., Bitzenhofer, S. H., Mulert, C., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.09.042 · Cited by 71
The Neuroimmunology of Schizophrenia
Annya, M., Smyth, Stephen, M., & Lawrie, S. M. (2013) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2013.11.3.107 · Cited by 68
Inflammation Theories in Psychotic Disorders: A Critical Review
Suvisaari, J., & Mantere, O. (2013) · Infectious Disorders - Drug Targets · doi:10.2174/18715265112129990032 · Cited by 68
Minocycline combination therapy with fluvoxamine in moderate‐to‐severe obsessive–compulsive disorder: A placebo‐controlled, double‐blind, randomized trial
Esalatmanesh, S., Abrishami, Z., Zeinoddini, A., Rahiminejad, F., Sadeghi, M., Najarzadegan, M., Shalbafan, M., & Akhondzadeh, S. (2016) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12430 · Cited by 65
Brain-immune crosstalk in the treatment of major depressive disorder
Branchi, I., Poggini, S., Capuron, L., Benedetti, F., Poletti, S., Tamouza, R., Drexhage, H. A., Penninx, B. W. J. H., & Pariante, C. M. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.016 · Cited by 66
Mind and body: how the health of the body impacts on neuropsychiatry
Renoir, T., Hasebe, K., & Gray, L. J. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00158 · Cited by 65
Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial
Dean, O. M., Maes, M., Ashton, M., Berk, L., Kanchanatawan, B., Sughondhabirom, A., Tangwongchai, S., Ng, C., Dowling, N., Malhi, G. S., et al. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.3.180 · Cited by 58
Self-citation
Psychopharmacology of the negative symptoms: Current status and prospects for progress
Davis, M. C., Horan, W. P., & Marder, S. R. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.010 · Cited by 60
Opportunities for the Development of Neuroimmune Therapies in Addiction
Ray, L. A., Roche, D. J. O., Heinzerling, K. G., & SHOPTAW, S. J. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801284-0.00012-9 · Cited by 60
Sleep and inflammatory markers in different psychiatric disorders
Krysta, K., Krzystanek, M., Bratek, A., & Krupka-Matuszczyk, I. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-015-1492-3 · Cited by 53
Microglia-neuron interactions in schizophrenia
Hartmann, S.-M., Heider, J., Wüst, R., Fallgatter, A. J., & Volkmer, H. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1345349 · Cited by 58
A pilot, open‐label, 8‐week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression
Soczynska, J. K., Kennedy, S. H., Alsuwaidan, M. T., Mansur, R. B., Li, M., McAndrews, M. P., Brietzke, E. M., Woldeyohannes, H. O., Taylor, V. H., & McIntyre, R. S. (2017) · Bipolar Disorders · doi:10.1111/bdi.12496 · Cited by 49
Minocycline Attenuates Stress-Induced Behavioral Changes via Its Anti-inflammatory Effects in an Animal Model of Post-traumatic Stress Disorder
Wang, W., Wang, R., Xu, J., Qin, X., Jiang, H., Khalid, A., Liu, D., Pan, F., Ho, C. S. H., & Ho, R. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00558 · Cited by 48
Substance use disorders: Psychoneuroimmunological mechanisms and new targets for therapy
Loftis, J. M., & Huckans, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.04.011 · Cited by 47
Profile of minocycline and its potential in the treatment of schizophrenia
Zhang, L., & Zhao, J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s64236 · Cited by 45
Between Dysbiosis, Maternal Immune Activation and Autism: Is There a Common Pathway?
Suprunowicz, M., Tomaszek, N., Urbaniak, A., Zackiewicz, K., Modzelewski, S., & Waszkiewicz, N. (2024) · Nutrients · doi:10.3390/nu16040549 · Cited by 44
Yokukansan promotes hippocampal neurogenesis associated with the suppression of activated microglia in Gunn rat
Furuya, M., Miyaoka, T., Tsumori, T., Liaury, K., Hashioka, S., Wake, R., Tsuchie, K., Fukushima, M., Ezoe, S., & Horiguchi, J. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-145 · Cited by 45
Formulation, Optimization, in Vivo Pharmacokinetic, Behavioral and Biochemical Estimations of Minocycline Loaded Chitosan Nanoparticles for Enhanced Brain Uptake
Nagpal, K., Singh, S. K., & Mishra, D. N. (2013) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c12-00732 · Cited by 43
Biotic acts of antibiotics
Aminov, R. I. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00241 · Cited by 40
Minocycline improves recognition memory and attenuates microglial activation in Gunn rat: A possible hyperbilirubinemia-induced animal model of schizophrenia
Liaury, K., Miyaoka, T., Tsumori, T., Furuya, M., Hashioka, S., Wake, R., Tsuchie, K., Fukushima, M., Limoa, E., Tanra, A. J., et al. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.12.017 · Cited by 40
Microglial inhibitory effect of ginseng ameliorates cognitive deficits and neuroinflammation following traumatic head injury in rats
Kumar, A., Rinwa, P., & Dhar, H. (2013) · Inflammopharmacology · doi:10.1007/s10787-013-0187-3 · Cited by 39
Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology
Data-Franco, J., Singh, A., Popovic, D., Ashton, M., Berk, M., Vieta, E., Figueira, M. L., & Dean, O. M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.09.004 · Cited by 38
Self-citation
Adjunctive minocycline for major mental disorders: A systematic review
Zheng, W., Zhu, X., Zhang, Q., Cheng, G., Cai, D.-B., He, J., Ng, C. H., Ungvari, G. S., Peng, X.-J., Ning, Y., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119858286 · Cited by 38
The possible role of CREB‐BDNF signaling pathway in neuroprotective effects of minocycline against alcohol‐induced neurodegeneration: molecular and behavioral evidences
Motaghinejad, M., Mashayekh, R., Motevalian, M., & Safari, S. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12584 · Cited by 34
Minocycline Treatment Reverses Sound Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome
Lovelace, J. W., Ethell, I. M., Binder, D. K., & Razak, K. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00771 · Cited by 39
An emerging role of cGMP in the treatment of schizophrenia: A review
Shim, S. S., Shuman, M. D., & Duncan, E. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.015 · Cited by 35
Crocin may be useful to prevent or treatment of alcohol induced neurodegeneration and neurobehavioral sequels via modulation of CREB/BDNF and Akt/GSK signaling pathway
Motaghinejad, M., Safari, S., Feizipour, S., & Sadr, S. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.01.017 · Cited by 34
Targeting neuroinflammation with minocycline in heavy drinkers
Petrakis, I. L., Ralevski, E., Gueorguieva, R. V., Sloan, M. E., Devine, L., Yoon, G., Arias, A. J., & Sofuoglu, M. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05205-3 · Cited by 41
Molecular, histological and behavioral evidences for neuroprotective effects of minocycline against nicotine-induced neurodegeneration and cognition impairment: Possible role of CREB-BDNF signaling pathway
Motaghinejad, M., Farokhi, N., Motevalian, M., & Safari, S. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112597 · Cited by 33
Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series
Butcher, N. J., Boot, E., Lang, A. E., Andrade, D. M., Vorstman, J. A. S., McDonald‐McGinn, D. M., & Bassett, A. S. (2018) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38708 · Cited by 34
Minocycline does not evoke anxiolytic and antidepressant-like effects in C57BL/6 mice
Vogt, M. A., Mallien, A. S., Pfeiffer, N., Inta, I. M., Gass, P., & Inta, D. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.12.015 · Cited by 34
A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia
Pérez‐Gómez, A., Carretero, M., Weber, N., Peterka, V., To, A., Titova, V., Solis, G. M., Osborn, O., & Petrascheck, M. (2018) · Nature Communications · doi:10.1038/s41467-018-07684-y · Cited by 35
Diagnostic Issues in Early-Onset Obsessive-Compulsive Disorder and their Treatment Implications
Burchi, E., & Pallanti, S. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180426151746 · Cited by 32
Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials
Zazula, R., Husain, M. I., Mohebbi, M., Walker, A. J., Chaudhry, I. B., Khoso, A. B., Ashton, M. M., Agustini, B., Husain, N., Deakin, J., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420965697 · Cited by 31
Self-citation
Anti-inflammatory effects of minocycline are mediated by retinoid signaling
Clemens, V., Regen, F., Bret, N. L., Heuser, I., & Hellmann‐Regen, J. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0460-x · Cited by 34
Microglia Sing the Prelude of Neuroinflammation-Associated Depression
Li, Q., Xie, Y., Lin, J., Li, M., Gu, Z., Xin, T., Zhang, Y., Lu, Q., Guo, Y., Xing, Y., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04575-w · Cited by 30
Minocycline prevents neuronal hyperexcitability and neuroinflammation in medial prefrontal cortex, as well as memory impairment caused by repeated toluene inhalation in adolescent rats
Cruz, S. L., Armenta-Reséndiz, M., Carranza‐Aguilar, C. J., & Galván, E. J. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.114980 · Cited by 28
Molecular and Biochemical Basis of Minocycline-Induced Hyperpigmentation—The Study on Normal Human Melanocytes Exposed to UVA and UVB Radiation
Rok, J., Rzepka, Z., Kowalska, J., Banach, K., Beberok, A., & Wrześniok, D. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073755 · Cited by 28
Modulation of high fat diet-induced microbiome changes, but not behaviour, by minocycline
Hasebe, K., Rivera, L. R., Smith, C. M., Allnutt, T. R., Crowley, T. M., Nelson, T. M., Dean, O. M., McGee, S. L., Walder, K. R., & Gray, L. J. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.09.001 · Cited by 26
Self-citation
Minocycline for Depressive Symptoms: a Meta-Analysis of Randomized, Double-Blinded, Placebo-Controlled Trials
Cai, D.-B., Zheng, W., Zhang, Q.-E., Ng, C. H., Ungvari, G. S., Huang, X., & Xiang, Y. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-019-09707-3 · Cited by 26
Minocycline as adjunctive treatment for treatment-resistant depression: study protocol for a double blind, placebo-controlled, randomized trial (MINDEP2)
Husain, M. I., Cullen, C., Umer, M., Carvalho, A. F., Kloiber, S. M., Meyer, J. H., Ortiz, A., Knyahnytska, Y., Husain, M. O., Giddens, J. L., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02553-9 · Cited by 26
Potential therapeutic approaches for Angelman syndrome
Bi, X., Sun, J., Ji, A. X., & Baudry, M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1115837 · Cited by 27
Alternative pharmacologic targets for the treatment of schizophrenia
Miyamoto, S., Jarskog, L. F., & Fleischhacker, W. W. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835d8296 · Cited by 23
Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia
Qurashi, I., Collins, J., Chaudhry, I. B., & Husain, N. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114527358 · Cited by 22
Stress- and drug-induced neuroimmune signaling as a therapeutic target for comorbid anxiety and substance use disorders
Smiley, C. E., & Wood, S. K. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108212 · Cited by 24
Antibiotics
Vardanyan, R., & Hruby, V. I. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-411492-0.00030-4 · Cited by 23
Managing epilepsy-associated depression: Serotonin enhancers or serotonin producers?
Singh, T., & Goel, R. K. (2016) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.10.007 · Cited by 22
Network-based drug repurposing for schizophrenia
Truong, T. T. T., Liu, Z. S.-J., Panizzutti, B., Kim, J. H., Dean, O. M., Berk, M., & Walder, K. R. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01805-6 · Cited by 22
Self-citation
Three Paths to Drug Discovery in Psychiatry
Berk, M., & Nierenberg, A. A. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14070858 · Cited by 21
Self-citation
The NLRP3 Inflammasome in Stress Response: Another Target for the Promiscuous Cannabidiol
dos Santos, A. H., Vila-Verde, C., Guimarães, F. S., Joca, S. R. L., & Lisboa, S. F. D. S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411101217 · Cited by 20
Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial
Fekadu, A., Mesfin, M., Medhin, G., Alem, A., Teferra, S., Gebre-Eyesus, T., Seboxa, T., Assefa, A., Hussein, J., Lemma, M. T., et al. (2013) · Trials · doi:10.1186/1745-6215-14-406 · Cited by 19
Tetracycline use in treating osteoarthritis: a systematic review
Platt, B. N., Jacobs, C. A., Conley, C., & Stone, A. V. (2021) · Inflammation Research · doi:10.1007/s00011-021-01435-4 · Cited by 18
Breaking free from the inflammatory trap of depression: Regulating the interplay between immune activation and plasticity to foster mental health
Branchi, I., Viglione, A., Vai, B., Cirulli, F., Benedetti, F., & Poggini, S. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103923 · Cited by 18
Neuroprotective Properties of Minocycline Against Methylphenidate-Induced Neurodegeneration: Possible Role of CREB/BDNF and Akt/GSK3 Signaling Pathways in Rat Hippocampus
Motaghinejad, M., & Motevalian, M. (2022) · Neurotoxicity Research · doi:10.1007/s12640-021-00454-7 · Cited by 17
Inhibition of brain retinoic acid catabolism: a mechanism for minocycline's pleiotropic actions?
Regen, F., Bret, N. L., Hildebrand, M., Herzog, I., Heuser, I., & Hellmann‐Regen, J. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1036116 · Cited by 20
A hypothetic role of minocycline as a neuroprotective agent against methylphenidate-induced neuronal mitochondrial dysfunction and tau protein hyper-phosphorylation: Possible role of PI3/Akt/GSK3β signaling pathway
Salehi, P., Shahmirzadi, Z. Y., Mirrezaei, F. S., Boushehri, F. S., Mayahi, F., Songhori, M., Abofazeli, M., Motaghinejad, M., & Safari, S. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.04.017 · Cited by 17
Single subcutaneous injection of the minocycline nanocomposite-loaded thermosensitive hydrogel for the effective attenuation of experimental autoimmune uveitis
Zhu, Y., Zhou, J., Hu, Y., Shi, H. R., Wu, Y., Pan, M., Chen, J., Mo, L., Bao, Z., Qu, J., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121836 · Cited by 15
Microbiota-Gut-Brain Axis and Antidepressant Treatment
Lachmansingh, D. A., Lavelle, A., Cryan, J. F., & Clarke, G. A. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_449 · Cited by 17
Biomarkers of stress resilience: A review
Paribello, P., Branchi, I., Viglione, A., Mancini, G. F., Morena, M., Campolongo, P., & Manchia, M. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104052 · Cited by 17
Where now for schizophrenia research?
Nutt, D., & Need, A. C. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.05.012 · Cited by 16
Antimanic activity of minocycline in a GBR12909-induced model of mania in mice: Possible role of antioxidant and neurotrophic mechanisms
Queiroz, A. I. G., Filho, A. J. M. C., Araújo, T. D. S., Lima, C. N. D. C., Machado, M. D. J. S., Carvalho, A. F., Vasconcelos, S. M. M., de Lucena, D. F., Quevedo, J., & Macêdo, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.07.053 · Cited by 16
Antipsychotic-like effect of minocycline in a rat model.
Dokuyucu, R., Kokaçya, M. H., İnanır, S., Çöpoğlu, Ü. S., & Erbaş, O. (2014) · PubMed Central · Cited by 14
Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder
Dodd, S., Fernandes, B. S., & Dean, O. M. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630175841 · Cited by 14
Self-citation
Association of Lyme Disease and Schizoaffective Disorder, Bipolar Type: Is it Inflammation Mediated?
Mattingley, D. W., & Koola, M. M. (2015) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.155660 · Cited by 12
Efficacy and tolerability of minocycline in depressive patients with or without treatment-resistant: a meta-analysis of randomized controlled trials
Qiu, Y., Duan, A., Yin, Z., Xie, M., Chen, Z., Sun, X., Wang, Z., & Zhang, X. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1139273 · Cited by 12
A Proteogenomic Approach to Unveiling the Complex Biology of the Microbiome
Pavelescu, L. A., Profir, M., Enache, R. M., Roşu, O. A., Creţoiu, S. M., & Gașpar, B. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910467 · Cited by 10
Modeling schizophrenia: uncovering novel therapeutic targets
Desbonnet, L., O’Tuathaigh, C. M. P., & Waddington, J. L. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.57 · Cited by 12
Predictors of successful anti-inflammatory drug trials in patients with schizophrenia: A meta-regression and critical commentary
Chandra, A., Miller, B. J., & Goldsmith, D. R. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.08.001 · Cited by 11
Anti-inflammatory treatment of bipolar depression: promise and disappointment
Berk, M., Vieta, E., & Dean, O. M. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30155-3 · Cited by 11
Self-citation
Minocycline modulates cytokine and gene expression profiles in the brain after whole-body exposure to radiation.
Mehrotra, S., Pecaut, M. J., & Gridley, D. S. (2014) · PubMed · Cited by 11
Minocycline-induced transient depersonalization: A case report
Shamout, Y., Sigal, A., & Litvinov, I. V. (2019) · SAGE Open Medical Case Reports · doi:10.1177/2050313x18823827 · Cited by 10
The Gut Microbiome: Insights for Personalized Medicine
Gurwitz, D. (2013) · Drug Development Research · doi:10.1002/ddr.21095 · Cited by 10

Authors: Dean, O. M., Data-Franco, J., Giorlando, F., & Berk, M.
Affiliations: Barwon Health (AU)
Mental Health Research Institute (AU)
The University of Melbourne (AU)
Corresponding author: Dean, Olivia M.
ORCID: Dean, Olivia M.
Giorlando, Francesco
Venue: CNS Drugs
Publisher: Springer Science and Business Media LLC
Published: 2012-05
Volume: 26
Issue: 5
Pages: 391-401
ISSN: 1172-7047 (ISSN-L)
DOI: 10.2165/11632000-000000000-00000
OpenAlex: W2159126784
Cited by: 131
References: 98
Citations by year: 2026: 5 · 2025: 2 · 2024: 10 · 2023: 7 · 2022: 8 · 2021: 6 · 2020: 13 · 2019: 8 · 2018: 7 · 2017: 6 · 2016: 7 · 2015: 11 · 2014: 18 · 2013: 19 · 2012: 4
FWCI: 12.12
Type: journal article
Language: en
Open access: closed
Locations: CNS Drugs (publishedVersion)
PubMed (publishedVersion)
Funders: Yale University
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: minocycline, adjunctive therapy, schizophrenia, bipolar depression, psychosis, nicotine dependence, obsessive-compulsive disorder, oxidative stress, neuroinflammation, glutamate excitotoxicity, neuroprotection, antioxidant activity, mood disorders, addiction
MeSH terms: Animals, Anti-Bacterial Agents, Mental Disorders, Humans, Inflammation, Minocycline, Nerve Growth Factors, Drug Delivery Systems, Oxidative Stress, Glutamic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Minocycline: Therapeutic Potential in Psychiatry

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks